Abstract

In the aftermath of the Women\u0027s Health Initiative (WHI) study, the firm ground of postmenopausal hormone therapy (HT) has been thoroughly shaken. While there was agreement that HT is indicated for the therapy of menopause-associated vasomotor symptoms and vulvovaginal atrophy, there was a general and often heated debate on the justification of additional indications. As a consequence, oral estrogen plus progestin HT use in the USA, for example, dropped precipitously, from 5.6 million users in 2001 to 2.5 million in 2003. This decline reflected the confusion, if not turmoil, among health-care providers and the general public. To worsen matters, the confusion was reinforced and amplified by the media. Luckily, the dust has settled, but the question on the purpose of long-term HT still remains.

Go to full publication

Categories

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.

We use cookies on our site to enable essential services and functionalities, and collect data in regards to visitor information to provide the best possible experience. By using our website, you agree to our Privacy Policy and our cookies usage. Cookie Policy Privacy Statement